Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2015
Pharma News, 2015
Gilead's new four-in-one HIV pill, Genvoya, wins US approval
Federal regulators have approved a new four-in-one combination pill to treat HIV, the virus that causes AIDS.
New vaccine candidate shows great promise at fighting respiratory syncytial virus
Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise ...
GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround
GlaxoSmithKline ($GSK) won FDA approval for an antibody designed to treat severe asthma, leading a pack of drugmakers at work on similar therapies as it seeks to bolster its respiratory busine...
CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC)
ROCKVILLE, MD, USA I November 4, 2015 I CASI Pharmaceuticals, Inc.
NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin
RALEIGH, NC, USA I November 4, 2015 I NephroGenex, Inc.
Bristol-Myers To Buy Cardioxyl Pharmaceuticals
Bristol-Myers Squibb Co.
Shire is paying $5.9B for Dyax in a defensive rare disease deal
Shire ($SHPG) signed a deal to buy Dyax ($DYAX) for $5.
Chemical Found In Illegal Ayahuasca Plant May Be Able To Completely Reverse Diabetes
Diabetes currently affects hundreds of millions of people worldwide.
New Data Continue to Characterize the Safety and Efficacy of XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis
NEW YORK--(BUSINESS WIRE)--Pfizer Inc.
Study suggests unprecedented 3-week hepatitis C cure
Yet another stunning victory in the drug battle against the liver-damaging hepatitis C virus (HCV) may be in the offing.
New finding helps explain why many alcohol drinkers also are smokers
Alcohol and nicotine use have long been known to go hand in hand.
Shionogi drug can kill viruses in 1 day
OSAKA -- Shionogi & Co.
5
6
7
8
9
10
11
12
13
